Torrent Pharma gets USFDA OAI status for Gujarat facility
Ahmedabad: Torrent Pharma has announced that the Company has received a communication from the US Food and Drug Administration (USFDA) determining the inspection classification of the manufacturing facility at Indrad, Gujarat as “Official Action Indicated” (OAI).Official Action Indicated (OAI) which means regulatory and/or administrative actions will be recommended."This...
Ahmedabad: Torrent Pharma has announced that the Company has received a communication from the US Food and Drug Administration (USFDA) determining the inspection classification of the manufacturing facility at Indrad, Gujarat as “Official Action Indicated” (OAI).
Official Action Indicated (OAI) which means regulatory and/or administrative actions will be recommended.
Medical Dialogues team had earlier reported that the USFDA had issued a "Form 483" with 3 observations at the end of the inspection at Torrent Pharma's manufacturing facility at Indrad, Gujarat.
Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in the therapeutic segments of cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology, and anti-infective segments. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.
Read also: Torrent Pharma to buy Curatio Healthcare for Rs 2,000 crores
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd